Author of

• 20167

  +

  P2.03 - Chemotherapy/Targeted Therapy (ID 704)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Chemotherapy/Targeted Therapy
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 23273

    +

    P2.03-002 - Impact of EGFR-Tyrosine Kinase Inhibitors for Postoperative Recurrent Non-Small Cell Lung Cancer Harboring EGFR Mutations (ID 7359)

    09:30 - 09:30  |  Author(s): S. Otani
    • Abstract

    Background:
    It is unclear whether there is a difference in the efficacy of treatment by EGFR-TKI between patients with postoperative recurrent non-small cell lung cancer (NSCLC) and those with stage IV NSCLC harboring EGFR mutations.
    
    Method:
    The records of NSCLC patients harboring EGFR mutations who were treated with gefitinib or erlotinib were retrospectively reviewed, and the treatment outcomes were evaluated. Moreover, we performed an immunohistochemical analysis of PD-L1 expression in tumor lesions of the postoperative recurrence group.
    
    Result:
    In 205 patients, both the progression-free survival time (9.4 versus 16.9 months) and the median survival time (24.7 versus 37.4 months) were significantly longer in the postoperative group than stage IV group. Additionally, multivariate analysis identified that postoperative recurrence was as an independent predictor of the PFS and OS, as well as performance status and smoking status. The PFS durations were 15.7 and 16.6 months for the high PD-L1 expression and low PD-L1 expression groups, respectively, and a significant difference was not observed (P = 0.73).
    
    Conclusion:
    The findings of this study provide a valuable rationale for considering postoperative recurrence as a predictive factor for favorable PFS and overall survival in patients with NSCLC harboring activating EGFR mutations receiving EGFR-TKI.